Pre‐existing cross‐reactive S2‐specific antibodies can prevent infection by blocking the fusion machinery of SARS‐CoV‐2, and IgA‐producing B cells have been demonstrated already after the first dose of vaccination [27, 45, 46, 47, 48, 49, 50, 51, 52]. This evidence concerns the gene CD79A and infection.